Full-Time
Updated on 8/8/2026
AI-powered diagnostics and drug development
No salary listed
Remote in UK + 2 more
More locations: Remote in Germany | Paris, France
Remote
PhD
See people who can refer or advise you
Owkin uses artificial intelligence to improve medical diagnostics and speed up the development of new drugs, specifically within the field of oncology. The company builds machine learning models that analyze diverse patient data, such as tissue samples and genetic records, to help researchers predict how patients will respond to specific treatments during clinical trials. Unlike many competitors, Owkin utilizes a collaborative network of academic centers and pharmaceutical companies to train its AI on vast, diverse datasets while maintaining strict data privacy. Their goal is to advance precision medicine by making the drug discovery process faster, less expensive, and more accurate for patients.
Company Size
201-500
Company Stage
Late Stage VC
Total Funding
$368M
Headquarters
Paris, France
Founded
2016
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Remote Work Options
Owkin, Sanofi expand AI collaboration to build drug development AI agents. Posted: 20 june 2026 Owkin and Sanofi are expanding their artificial intelligence collaboration through a multi-year agreement to co-develop AI-enabled biopharma agents for drug research and development. Posted: 22 june 2026 Healthcare innovation continues to evolve at an extraordinary pace - driven by advances in AI, digital health, virtual care, and new models of medical education. At the centre of many of these conversations is Prof. Shafi Ahmed, its Chairman and... Posted: 19 june 2026 The trial marks the first time a vaccine whose active ingredient was entirely designed by AI has been tested in humans, researchers at the University of Cambridge in the U.K. The experimental jab is intended to be a "universal vaccine"...
Cleveland Clinic Abu Dhabi collaborates with Owkin to launch world's first clinical AI scientist. Faizan Hashmi Published June 17, 2026 | 02:30 PM ABU DHABI, (UrduPoint / Pakistan Point News / WAM - 17th Jun, 2026) Cleveland Clinic Abu Dhabi today announced a collaboration with Owkin to launch 'Aila,' the world's first clinical artificial intelligence scientist. The advanced AI platform is designed to support real-time clinical decision-making and accelerate medical research using real patient data. 'Aila' is designed to reason across complex datasets, generate actionable medical insights, and continuously learn. It transforms how clinicians interact with data - enabling faster, more informed, and more precise decision-making at the point of care. 'Aila' is designed to function as a clinical AI scientist, unlocking and connecting datasets. Through a secure, intuitive natural-language interface, physicians will be able to query vast amounts of clinical data in real time and receive insights that previously required days or weeks of manual analysis. The platform is expected to transform fragmented information into a unified, queryable knowledge layer that delivers meaningful insights at the critical moment when clinical decisions are made. "This collaboration reflects our commitment to innovation and our responsibility to actively create the future of healthcare," said Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi. "By responsibly harnessing advanced AI built on real patient data, we are empowering our caregivers with powerful tools that enhance clinical judgment, advance discovery, and ultimately improve outcomes for the patients and communities we serve." The initial deployment of 'Aila' will focus on prostate cancer, integrating multiple clinical data sources including electronic health records, physician notes, pathology reports, and medical imaging. Supported by the UAE's AI-enabled infrastructure and built on Owkin's agentic K Pro - purpose-built for biology platform, 'Aila' is engineered to scale across additional medical specialities and increasingly complex data modalities. Over time, the platform is designed to incorporate advanced data types such as multi-omics and genomic data, supporting large-scale precision medicine initiatives. Facebook Twitter Reddit Pinterest Whatsapp
Sanofi and owkin partner to co-develop agentic AI tools for drug discovery. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call
Sanofi expands Owkin partnership for purpose-built AI agents. June 8, 2026 Sanofi has signed a multi-year collaboration agreement with Owkin, the Franco-American agentic AI company, to co-develop bespoke AI agents deployed through K Pro, Owkin's AI Scientist platform - extending a partnership that dates to 2021 and now covers Sanofi's full pharmaceutical value chain. The arrangement includes a five-year license for K Pro and positions Owkin as the end-to-end builder of purpose-built agents integrated into Sanofi's existing agentic AI workflows. Financial terms were not disclosed. The collaboration builds on a prior EUR 90 million (approximately USD 104 million) strategic partnership initiated in 2021, which focused on target identification across four oncology programs and was later expanded to include drug positioning for Sanofi's immunology pipeline. The current agreement represents a structural shift: where earlier work was program-specific, the K Pro license is platform-wide, designed to operate across Sanofi's entire R\&D continuum from early discovery through clinical development. K Pro is described by Owkin as an agentic AI platform built on multimodal biological data - including genomics, histopathology imaging, and clinical outcomes - combined with what the company calls biological reasoning models. Central to the architecture is Owkin Zero, a 32-billion parameter model trained on approximately 10 million curated biomedical question-and-answer pairs, designed to execute mechanistic scientific reasoning rather than general text retrieval. Proprietary histology foundation models, including H0 and iBOT, trained on more than 200,000 pathologist annotations, provide a spatial tissue-level reasoning layer. Under the Sanofi arrangement, Owkin will develop AI agents that autonomously perform complex tasks - competitive intelligence, landscape forecasting, target evaluation, and clinical decision support - deployed within Sanofi's internal governance and security frameworks. The scope is deliberately enterprise-wide rather than indication-specific. Owkin previously entered a three-year license agreement with AstraZeneca for K Pro in May 2026, where initial capabilities focused on competitive intelligence for specific targets and assets. The Sanofi arrangement appears broader, covering co-development of novel agents across multiple workflow categories rather than a single defined use case. Industry and transaction context. The deal reflects a pattern among large pharma companies of sourcing AI platform capabilities through time-limited licensing arrangements with a vendor-led build component, rather than through acquisitions or equity stakes. The AstraZeneca K Pro deal, announced three weeks prior, followed the same structural logic - a defined term, Owkin-led agent development, and deployment within the pharma's own IT environment. Two major pharma companies licensing the same platform within weeks of each other is notable for a privately held AI vendor and suggests Owkin is actively converting its prior pharma relationships into recurring platform revenue. Sanofi's AI partnering behavior has been consistent across modalities. In January 2026, Sanofi extended its collaboration with CytoReason for AI-powered computational disease modeling in a deal valued at up to USD 16 million - its third expansion of that relationship. The CytoReason deal is structured around proprietary disease models and evidence graphs rather than agentic workflow execution, illustrating that Sanofi is layering multiple AI vendors with distinct technical approaches rather than consolidating on a single platform. The K Pro collaboration occupies a different functional layer: autonomous agent execution across the R\&D value chain rather than disease-specific predictive modeling. Sanofi's broader AI vendor portfolio also includes a worldwide exclusive license with Earendil Labs for AI-discovered bispecific antibodies in autoimmune disease, announced in April 2025 with USD 125 million upfront and up to USD 1.72 billion in milestones. That deal follows traditional biopharma licensing economics tied to specific molecules. The K Pro arrangement sits in a structurally different category - platform access rather than asset acquisition - and the two approaches are complementary rather than substitutive within Sanofi's AI sourcing strategy. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Owkin has announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, backed by a five-year licence for K Pro, Owkin's AI scientist platform. The partnership will focus on creating AI-driven agents designed to autonomously perform complex tasks throughout drug research and development. The companies have collaborated since 2021 through a €90 million strategic partnership focused on oncology target identification and patient subgrouping. Owkin will lead the end-to-end development of AI agents deployed through K Pro, which combines multimodal patient data with specialised biological AI systems to support pharmaceutical workflows from early discovery through clinical development. The collaboration aims to embed agentic AI systems into Sanofi's existing workflows, enabling faster and more precise decision-making across the drug development lifecycle.